Intrinsic Edge Capital Management LLC acquired a new position in Amarin Corporation PLC (NASDAQ:AMRN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 180,000 shares of the biopharmaceutical company’s stock, valued at approximately $725,000. Intrinsic Edge Capital Management LLC owned about 0.07% of Amarin Corporation PLC as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of AMRN. Wells Fargo & Company MN grew its position in shares of Amarin Corporation PLC by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the last quarter. Ameriprise Financial Inc. grew its position in Amarin Corporation PLC by 0.9% during the 1st quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock worth $1,266,000 after purchasing an additional 3,413 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in Amarin Corporation PLC by 1.4% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock worth $460,000 after purchasing an additional 2,050 shares during the last quarter. JPMorgan Chase & Co. grew its position in Amarin Corporation PLC by 27.1% during the 1st quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 7,580 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in Amarin Corporation PLC by 13.3% during the 1st quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company’s stock worth $1,707,000 after purchasing an additional 62,800 shares during the last quarter. 37.76% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/180000-shares-in-amarin-corporation-plc-amrn-purchased-by-intrinsic-edge-capital-management-llc/1615534.html.

Amarin Corporation PLC (NASDAQ AMRN) traded up 1.15% during mid-day trading on Friday, reaching $3.51. 837,349 shares of the company’s stock traded hands. Amarin Corporation PLC has a 52 week low of $2.65 and a 52 week high of $4.47. The stock’s 50 day moving average is $3.28 and its 200-day moving average is $3.32. The stock’s market capitalization is $950.48 million.

Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. The company’s revenue for the quarter was up 37.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.07) EPS. On average, equities analysts anticipate that Amarin Corporation PLC will post ($0.21) EPS for the current year.

AMRN has been the topic of several research analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $5.00 target price on shares of Amarin Corporation PLC in a research report on Monday, June 12th. BidaskClub downgraded shares of Amarin Corporation PLC from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 24th. Zacks Investment Research downgraded shares of Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research report on Wednesday, August 9th. Finally, ValuEngine raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Amarin Corporation PLC currently has an average rating of “Buy” and a consensus price target of $7.20.

In related news, insider Steven B. Ketchum sold 63,479 shares of Amarin Corporation PLC stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $3.48, for a total transaction of $220,906.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.72% of the company’s stock.

Amarin Corporation PLC Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Corporation PLC (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.